neural cells

[Denali Therapeutics, Inc.] Denali Therapeutics, Inc. announced that its strategic partner Takeda Pharmaceutical Company Limited has exercised an option to co-develop and co-commercialize DNL593, an investigational, brain-penetrant progranulin replacement therapy for the potential treatment of frontotemporal dementia-granulin.

[Molecular Psychiatry] Scientists utilized patient-derived iPSCs to generate 3D cerebral organoids to model neuropathology of schizophrenia during its early-arising neurodevelopmental period.

[Prilenia Therapeutics B.V. (Business Wire, Inc.)] Prilenia Therapeutics B.V., a clinical stage biotech company focused on developing novel treatments for neurodegenerative and neurodevelopmental disorders, announced that the US FDA has granted Fast Track designation to pridopidine for development as a potential treatment for Huntington’s Disease.

[Nature Communications] Tamoxifen-inducible and microglia-specific depletion of polyglutamine binding protein 1 (PQBP1) in primary culture in vitro and mouse brain in vivo showed that PQBP1 was essential for sensing-tau to induce nuclear translocation of nuclear factor κB (NFκB).

[Cell Death Discovery] Investigators concluded that both Beclin1 and Puma played essential roles in the neuronal death caused by the induction of aberrant autophagy in Alzheimer’s disease and that targeting their interaction could be vital to understand the crosstalk of autophagy and apoptosis.

[Acta Neuropathologica Communications] Whether sensory neuronal activity is important for tumor progression remains unknown. Researchers suggested that sensory innervations regulate melanoma progression, indicating that manipulation of sensory neurons’ activity may provide a valuable tool to improve melanoma patients’ outcomes.